Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Improved Curcumin Loading, Release, Solubility and Toxicity by Tuning the Molar Ratio of Cross-Linker to Β-Cyclodextrin Publisher Pubmed



Gholibegloo E1, 2 ; Mortezazadeh T3 ; Salehian F2 ; Ramazani A1 ; Amanlou M4 ; Khoobi M2, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran
  2. 2. Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center (MBRC), Faculty of Pharmacy, Tehran Univercity of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Physics, School of Medicine, Tabriz University of Medical Science, Tabriz, Iran
  4. 4. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14176-53955, Iran
  5. 5. Biomaterials Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, 1417614411, Iran

Source: Carbohydrate Polymers Published:2019


Abstract

A novel β-cyclodextrin-based nanosponge (CDNS) was proposed as curcumin (CUR) delivery system improving pharmacokinetics and anticancer activity of CUR. The effect of molar ratio of Epiclon (EPI) as cross-linker and β-cyclodextrin (βCD) on the porosity, surface area, swelling ratio, CUR solubility and loading capacity, rate of drug release and selective toxicity of the CDNSs was fully investigated. The high degree of cross-linking led to the formation of mesoporous CDNS having high specific surface area and high loading capacity. All CUR-free CDNSs showed no toxicity against MCF 10A and 4T1 cells as normal and cancerous cells, respectively. While CDNSs-CUR exhibited selective toxicity against cancerous cells. In sum, high CUR aqueous solubility, significant loading and controllable release of the CUR, outstanding and selective toxicity against cancerous cells make CDNS8-CUR (EPI/βCD = 8) as promising candidate for further study in the cancer therapy. © 2019 Elsevier Ltd
Experts (# of related papers)